Group 1 - The board of directors of Shanghai Xinzhi Software Co., Ltd. held its 23rd meeting on August 29, 2025, with all 7 directors present, confirming the legality and validity of the meeting [1] - The board approved the 2025 semi-annual report, which objectively reflects the company's operational and financial status, adhering to relevant regulations [2][4] - The board also approved the special report on the storage and use of raised funds for the first half of 2025, confirming that the funds were stored in dedicated accounts and used appropriately [2][3] - A semi-annual evaluation report on the company's quality improvement and efficiency enhancement action plan for 2025 was also approved, with unanimous support from the board [4]

Core Points - The company held its 15th meeting of the 10th Board of Directors via telecommunication, with all 9 directors present, and confirmed compliance with legal and regulatory requirements [1] - The board approved the report on asset impairment provision and asset write-off for the first half of 2025, totaling a write-off of 2,088,101.13 yuan for bad debt provisions [2] - The board also approved the half-year report for 2025, which will be disclosed on August 30, 2025, after being reviewed by the audit committee [2] - A special report on the use of raised funds for the first half of 2025 was approved, with unanimous support from the board [2] - The board reviewed a risk assessment report regarding Shanghai Electric Group Financial Co., Ltd., with certain directors abstaining from voting due to conflicts of interest [3] - The board approved an increase in the amount of daily related party transactions for 2025, with independent directors reviewing the proposal [3] - The board approved amendments to the company's governance system to align with the latest regulatory requirements and improve operational standards [4][5]

Core Viewpoint - The report provides a comprehensive overview of the fundraising activities and usage of funds by Liaoning Chengda Biological Co., Ltd. for the first half of 2025, highlighting the total amount raised, the allocation of funds, and the management of surplus funds [1][2][3]. Fundraising Overview - The total amount raised from the initial public offering (IPO) was RMB 4,581,500,000, with all funds received by October 25, 2021 [1]. - As of June 30, 2025, the balance in the fundraising account was RMB 434,929,298.11, after utilizing RMB 1,423,828,419.14 for various projects [1][2]. Fund Usage and Management - The company has invested a total of RMB 783,049,371.27 from the raised funds, with specific allocations for projects such as the human vaccine construction project and the biological product research and development base [1][3]. - The company has established a fundraising management system to ensure the proper use and efficiency of the funds, adhering to relevant laws and regulations [1][3]. Project Investment and Adjustments - The company has made adjustments to its fundraising projects, including the completion of the human vaccine construction project and the initiation of cash management for idle funds, allowing for investment in safe financial products [3][4]. - A total of RMB 69,000,000 from over-raised funds was permanently allocated to supplement working capital [4][5]. Financial Management Practices - The company has not used idle funds for temporary working capital supplementation during the reporting period, ensuring that all funds are allocated according to the planned projects [3][4]. - The company has also engaged in cash management practices, allowing for the investment of up to RMB 1.6 billion in safe financial products, with a focus on maintaining liquidity and security [3][4]. Compliance and Reporting - The company has complied with all relevant regulations regarding the use and disclosure of fundraising activities, ensuring transparency and accountability in its financial practices [4][5]. - No violations of fundraising usage and management regulations were reported during the period [4][5].

Fundraising Overview - The company raised a total of RMB 600 million through the issuance of 6 million convertible bonds at a face value of RMB 100 each, with the funds fully received by August 17, 2023 [1] - After deducting issuance costs of RMB 11,249,651.93, the net amount raised was RMB 588,750,348.07 [1] - As of June 30, 2025, the company had utilized RMB 591,208,771.55 of the raised funds, leaving a balance of RMB 1,010,405.54 [1][4] Fund Management - The company has established a management system for the raised funds, ensuring they are stored in dedicated accounts to safeguard investor interests [1] - The funds are held in special accounts at China Minsheng Bank, CITIC Bank, and Industrial Bank, with regulatory agreements in place to ensure proper oversight [1] Fund Utilization - The company has not made any changes to the implementation locations or methods for the fundraising projects during the reporting period [2] - A total of RMB 73,540,370.58 has been approved for replacement of pre-invested funds and issuance costs, which has been completed as of June 30, 2025 [2] - There are no instances of idle funds being temporarily used to supplement working capital, nor are there any surplus funds or over-raised funds being utilized [3][4] Project Status - As of June 30, 2025, the precision optical lens production project has reached a state of readiness for use, although no benefits have been realized yet [3] - The company has confirmed that there are no significant changes in the feasibility of the fundraising projects [3]

广西柳药集团股份有限公司 募集资金管理制度 (2025年8月修订) 第一章 总 则 同一投资项目所需资金原则上应当在同一募集资金专户存储。公司存在两次 以上融资的，应当分别设置募集资金专户。实际募集资金净额超过计划募集资金 金额（以下简称"超募资金"）也应当存放于募集资金专户管理。 第二条 本制度所称募集资金，是指公司通过发行股票或者其他具有股权性 质的证券，向投资者募集并用于特定用途的资金，但不包括公司实施股权激励计 划募集的资金。 第六条 公司应当在募集资金到账后 1 个月内与保荐人或者独立财务顾问、 商业银行签订募集资金专户存储三方监管协议。该协议至少应当包括以下内容： 第一条 为进一步规范广西柳药集团股份有限公司（以下简称"公司"）对募 集资金的使用和管理，提高募集资金的使用效率和效益，维护投资者的合法权益， 根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司募集资金 监管规则》《上海证券交易所股票上市规则》《上海证券交易所上市公司自律监 管指引第 1 号——规范运作》等相关法律、法规及规范性文件和《广西柳药集团 股份有限公司章程》（以下简称"《公司章程》"）的有关规定，结合公司实际 情况 ...

Summary of Key Points Core Viewpoint - The company, Shanghai Aohua Endoscope Co., Ltd., has announced a delay in part of its fundraising investment projects and an adjustment to its internal investment structure, which is deemed necessary for optimizing the use of raised funds and ensuring the steady implementation of investment projects [1][6]. Group 1: Fundraising Overview - The company was approved to issue 33.34 million shares at a price of 22.50 RMB per share, raising a total of 750.15 million RMB, with a net amount received of 691.40 million RMB after deducting issuance costs [1][2]. - The funds have been stored in a dedicated account, with agreements signed for three-party and four-party supervision [2]. Group 2: Use of Funds - As of June 30, 2025, a total of 544.86 million RMB has been invested out of the committed 640 million RMB for the projects [2]. Group 3: Project Delay Details - The "Medical Endoscope Production Base Construction Project" has been delayed due to adjustments in production layout, approval of external water supply engineering plans, and changes in external power supply lines [3][4]. - The new expected completion date for the project has been extended to August 2026 [5]. Group 4: Internal Investment Structure Adjustment - The internal investment structure for the "Medical Endoscope Production Base Construction Project" has been adjusted, maintaining the total investment amount while optimizing the allocation of funds [4]. - The adjustments include increasing amounts for construction and land costs while reducing expenditures for equipment purchase and installation [4]. Group 5: Impact of Adjustments - The adjustments are expected to optimize the investment structure and will not adversely affect the company's normal operations or change the intended use of the raised funds [5][6]. - The decisions made are in compliance with relevant regulations and do not harm shareholder interests [6]. Group 6: Approval Process - The board of directors and the supervisory board have both approved the adjustments, confirming that they align with the company's actual situation and future plans [5][6].

Fundraising Overview - The company raised a total of RMB 463,946,049.85 from the issuance of 16,840,147 shares at a price of RMB 27.55 per share, with a net amount of RMB 418,893,117.00 after deducting issuance costs and taxes [1][2] - As of June 30, 2025, the net amount of raised funds was RMB 405,874,233.95, with additional interest income from various financial products totaling RMB 18,393,798.12 [2][3] Fund Usage and Management - The company has utilized RMB 307,253,143.57 from the raised funds in previous years and RMB 14,871,801.68 in the current period for investment projects, leaving a balance of RMB 91,476,794.04 for working capital [2][3] - The company has established a management system for the raised funds, ensuring compliance with regulations and maintaining a dedicated account for fund storage [1][2] Cash Management - The company has approved the use of up to RMB 80 million of temporarily idle funds for cash management, investing in low-risk financial products to ensure liquidity and safety [2][3] - The total income from cash management activities during the reporting period was RMB 463,821.98 [3] Surplus Fund Usage - The company has used surplus funds of RMB 9.25 million to repay bank loans, which is approximately 29.99% of the total surplus funds raised [3] - As of June 30, 2025, the company has utilized RMB 1.85 million of surplus funds for short-term bank loan repayment, with no other instances of using surplus funds for working capital [3] Project Completion and Fund Reallocation - The company has completed the "Industrial Robot and Intelligent Equipment Production Base Project" and the "R&D Center Construction Project," reallocating surplus funds of RMB 40,677,887.69 and RMB 50,798,906.35 respectively to working capital [3][4] - The company has not made any changes to the fundraising projects during the reporting period [3][4] Compliance and Reporting - The company has confirmed that all disclosed information regarding the use of raised funds is timely, truthful, accurate, and complete, with no significant violations in fund usage [3][4] - The special report on fundraising was approved by the board of directors on August 28, 2025 [3]

北京英诺特生物技术股份有限公司 （2025年8月修订） 北京英诺特生物技术股份有限公司 募集资金使用管理办法 第一章 总则 第一条 为规范北京英诺特生物技术股份有限公司（以下简称"公 司"）募集资金的使用与管理，提高募集资金使用效益，切实保护投 资者利益，根据《中华人民共和国公司法》、《中华人民共和国证券 法》（以下简称"《证券法》"）、《上市公司募集资金监管规则》、 《首次公开发行股票注册管理办法》、《上海证券交易所科创板股票 上市规则》、《上海证券交易所科创板上市公司自律监管指引第 1 号 ——规范运作》等相关法律法规和规范性文件以及《公司章程》的规 定，结合公司实际情况，制定本办法。 募集资金使用管理办法 第二条 本办法所称募集资金是指公司通过发行股票或者其他具 有股权性质的证券向投资者募集并用于特定用途的资金，但不包括公 司实施股权激励计划募集的资金。 第三条 公司董事、高级管理人员应当勤勉尽责，确保公司募集 资金安全，不得操控公司擅自或者变相改变募集资金用途。 公司董事会应当科学、审慎地对募集资金投资项目（以下简称"募 投项目"）的可行性进行充分论证，确信投资项目有利于增强公司竞 争能力和创新能力， ...

Group 1 - The core viewpoint of the article is that Qianjiang Water Conservancy Development Co., Ltd. has completed certain fundraising projects and plans to use the surplus funds for other fundraising projects, which is a prudent decision to enhance the efficiency of fund utilization and support the company's ongoing business development [1][7][8]. Group 2 - The company raised a total of RMB 581,020,898.64 through a targeted issuance of 66,630,837 shares at a price of RMB 8.72 per share, with net funds amounting to RMB 573,177,116.51 after deducting fees [1]. - The fundraising projects included the Fuzhou Jiangyin Port City Economic Zone Sewage Treatment Plant Mid-term Project and the Changshan Overseas Chinese Town Sewage Treatment Plant Expansion and Upgrade Project, with a total investment of RMB 178,849.79 million and an intended fundraising amount of RMB 57,237.06 million [2][6]. - The completed fundraising projects include the "Hucun Water Plant Project (Phase I)", "Lanxi City Dengsheng Water Plant Project", "Fuzhou Jiangyin Port City Economic Zone Sewage Treatment Plant Mid-term Project (Phase I)", and "Changshan Overseas Chinese Town Sewage Treatment Plant Expansion and Upgrade Project", with a total surplus of RMB 10,685.60 million [6][8]. Group 3 - The main reasons for the surplus in fundraising are strict adherence to regulations, effective resource allocation, and cost control during project implementation, which led to savings in construction costs [6][7]. - The company plans to allocate the surplus funds of RMB 10,685.60 million to ongoing projects, specifically the "Yongkang City Urban Sewage Treatment Plant (Phase V)" and "Pinghu City Dushan Port Industrial Water Plant (Phase III)" [6][8]. - The total unpaid amount for the completed projects is RMB 6,592.42 million, which will remain in the fundraising special account for future payments [6][8]. Group 4 - The decision to use surplus funds for other projects is seen as beneficial for meeting funding needs, avoiding idle funds, and enhancing economic efficiency, aligning with the company's operational development and shareholder interests [7][8]. - The proposal for reallocating surplus funds has been approved by the company's board, ensuring compliance with relevant regulations and guidelines [8][9].

Summary of Key Points Core Viewpoint - The company has completed certain fundraising investment projects and plans to permanently supplement its working capital with the surplus funds from these projects [1][4]. Fundraising Basic Situation - The company issued 23,290,278 shares at a price of RMB 48.98 per share, raising a total of RMB 1,140.7578 million, with a net amount of RMB 1,054.3036 million after deducting issuance costs [2][3]. Investment Project Situation - The total planned investment for the fundraising projects was RMB 999.984 million, with RMB 985.6759 million allocated from the raised funds [2][3]. Surplus Funds Usage and Reasons - The surplus funds from the "Medical Devices and Biological Testing Reagent Industrialization Project" will be permanently used to supplement working capital, with the remaining funds to cover outstanding payments such as salaries and bonuses [3][4]. - The surplus was achieved through strict adherence to fundraising regulations, cost control, and efficient resource allocation during project implementation [3][4]. Approval Process - The decision to conclude the fundraising project and allocate surplus funds was approved by the company's board and will be submitted for shareholder meeting approval [4][6]. Supervisory Opinions - The supervisory board confirmed that the decision aligns with relevant regulations and is in the best interest of the company and its shareholders, ensuring no adverse impact on operations [4][6]. Sponsor's Verification Opinion - The sponsor, CITIC Securities, has no objections to the company's decision regarding the conclusion of the fundraising project and the allocation of surplus funds, confirming compliance with regulatory requirements [5][6].